• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
LOGC

LOGC

ContextLogic Inc.

OTCConsumer CyclicalSpecialty RetailUS

USD9.00

-0.04 (-0.44%)

Rating:C

Company Profile

CEO

Mark Ward

IPO Date

2020-12-16

Sector

Consumer Cyclical

Industry

Specialty Retail

Exchange

OTC

Country

US

Market Metrics

Open

$9.04

Prev. Close

$9.04

Day Low

$8.96

Day High

$9.10

52W Low

$6.40

52W High

$9.15

Market Cap

$0.25B

Volume

0.05M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

28.0%

Avg Negative

2.0%

Avg Neutral

69.9%

News Feed

LogicBio Therapeutics to Participate in William Blair Biotech Focus Conference 2021

PRNewsWire·7/8/2021·↑ positive

LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia

PRNewsWire·6/2/2021·↑ positive

LogicBio Therapeutics to Participate in Upcoming Investor Conferences

PRNewsWire·6/1/2021·↑ positive

LogicBio Therapeutics Promotes Daniel Gruskin, MD, to Chief Medical Officer and Announces Additional Leadership Appointments

PRNewsWire·5/19/2021·↑ positive

LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update

PRNewsWire·5/10/2021·↑ positive

LogicBio Therapeutics Strengthens Management Team with Key Appointments

PRNewsWire·5/10/2021·↓ negative

LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia

PRNewsWire·5/3/2021·↑ positive

Arix Bioscience investee LogicBio signs strategic collaboration with CANBridge Pharma

Proactive Investors·4/27/2021·↑ positive

LOGC Stock: Over 8% Increase Pre-Market Explanation

Pulse2·4/27/2021·↑ positive

LogicBio Therapeutics Announces Clinical and Corporate Updates

PRNewsWire·4/27/2021·↑ positive